A Protein L -Based Immunodiagnostic Approach Utilizing Time-Resolved Forster Resonance Energy Transfer by Hepojoki, Satu et al.
A Protein L -Based Immunodiagnostic Approach Utilizing
Time-Resolved Fo¨rster Resonance Energy Transfer
Satu Hepojoki1, Visa Nurmi1, Antti Vaheri1,2, Klaus Hedman1,2, Olli Vapalahti1,2,3, Jussi Hepojoki1*
1Department of Virology, Haartman Institute, University of Helsinki, Helsinki, Finland, 2Helsinki University Central Hospital, Hospital District of Helsinki and Uusimaa,
Laboratory Services, HUSLAB, Helsinki, Finland, 3Department of Veterinary Biosciences, University of Helsinki, Helsinki, Finland
Abstract
Chelated lanthanides such as europium (Eu) have uniquely long fluorescence emission half-lives permitting their use in
time-resolved fluorescence (TRF) assays. In Fo¨rster resonance energy transfer (FRET) a donor fluorophore transfers its
emission energy to an acceptor fluorophore if in sufficiently close proximity. The use of time-resolved (TR) FRET minimizes
the autofluorescence of molecules present in biological samples. In this report, we describe a homogenous immunoassay
prototype utilizing TR-FRET for detection of antibodies in solution. The assay is based on labeled protein L, a bacterial
protein that binds to immunoglobulin (Ig) light chain, and labeled antigen, which upon association with the same Ig
molecule produce a TR-FRET active complex. We show that the approach is functional and can be utilized for both mono-
and polyvalent antigens. We also compare the assay performance to that of another homogenous TR-FRET immunoassay
reported earlier. This novel assay may have wide utility in infectious disease point-of-care diagnostics.
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Introduction
Biological sample materials are prone to autofluorescence,
which can be minimized by utilizing time-resolved fluorometry
(TRF). TRF takes advantage of unique rare earth elements called
lanthanides, such as europium, which have exceptionally long
fluorescence emission half-lives. In Fo¨rster resonance energy
transfer (FRET), energy is transferred between two fluorophores,
the donor and the acceptor [1]. Time-resolved FRET (TR-FRET)
unites the properties of TRF and FRET, which is especially
advantageous when analyzing biological samples. As TR-FRET
-based methods induce relatively low background fluorescence,
this technique has been widely applied in medical research and
diagnostics [2–10]. Overall, TR-FRET -based applications offer a
viable alternative for the conventional multistep diagnostic tests,
such as enzyme-linked immunosorbent assay (ELISA).
We recently developed for detection of antibodies a TR-FRET
-based homogeneous immunoassay denoted ‘‘FRET-bridge’’
which employs antigens separately labeled with donor- and
acceptor-fluorophores [11]. In the FRET-bridge assay simulta-
neous binding of donor- and acceptor-labeled antigens to an
immunoglobulin (Ig) G molecule can be measured by TR-FRET.
The FRET-bridge assay was set up utilizing a tetrameric antigen,
streptavidin (SA), due to its commercial availability with fluores-
cent labels. However, when evaluating the performance of FRET-
bridge assay using monovalent antigens, we observed decreased
sensitivity. The FRET-bridge assay requires each antigen to be
separately labeled with two fluorophores, which is expensive and
also potentially hampered by the random attachment of the labels
that might affect the immunologically important epitopes. As the
efficiency of FRET is dependent on the distance between the
donor and acceptor fluorophores, we reasoned that in an ideal
TR-FRET assay both of the two fluorophores should preferentially
bind to the same Fab-arm of the Ig molecule. This could not only
improve the assay sensitivity by bringing the interacting fluor-
ophores closer, but would also reduce the number of labeling
reactions required for multiple assays, because the same Ig-binding
molecule could be used in combination with a variety of antigens.
In addition, one IgG molecule could form two FRET-pairs one
with each Fab-arm, thus likely increasing the signal intensity.
To implement the above-mentioned idea, we chose to use
protein L, a bacterial surface protein originally derived from
Finegoldia (formerly Peptostreptococcus) magnus [12] as the Ig-
binding molecule. Protein L binds the Ig kappa (k) light chain
without interfering with the antigen recognition [12]. Through k
light chain interaction protein L is capable of binding to all
immunoglobulin classes (IgG, IgM, IgA, IgE and IgD) [13].
Additionally, protein L binds to single-chain variable fragments
(scFv) and Fab fragments bearing k light chains [14,15].
Therefore, protein L binds to a wider range of Ig classes and
subclasses than the other antibody-binding proteins, such as
protein A and G [16,17].
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We chose to use europium-chelate (Eu) as the donor due to its
spectral properties. Fluorescent Eu-chelates exhibit large Stoke’s
shifts with no overlap between the excitation (at 320 nm in our
assay) and emission (at around 615 nm) wavelenghts. The emission
wavelength is above the background fluorescense from biological
samples (usually 300–600 nm) [18]. For FRET to occur, spectral
overlap of the donor emission and acceptor absorption is required.
AlexaFluor647 (AF647, excitation maximum at 650 nm) is
commonly used as a FRET-pair for Eu, due to spectral overlap
of these fluorophores.
Here, we describe a novel approach for detection of antibodies
in solution. The approach relies on fluorophore-labeled recombi-
nant protein L, which in conjunction with fluorophore-labeled
antigen induce TR-FRET signal in the presence of antibody
specific to the antigen. This novel approach is simpler than the
FRET-bridge assay [11], because it requires the antigen to be
labeled with only a single fluorophore. Moreover, the assay based
on labeled protein L is highly versatile, detecting all antibody
classes in combination with a practically unlimited range of
antigens. Herein we provide the proof-of-principle and determine
the assay performance for the novel approach utilizing both
monomeric and tetrameric antigens. In addition, we compare the
performances of the protein L and FRET-bridge immunoassays
with particular emphasis on the mono- versus multimeric property
of the antigen.
Materials and Methods
Ethics statement
The human serum sample used in this study was obtained under
the research permit of ethical committee of Hospital District of
Helsinki and Uusimaa, number 553/E6/2001. A written informed
consent was obtained from the donor.
Proteins and antibodies
Recombinant protein L was purchased from Thermo Scientific
(Pierce Protein Biology Products) and separately labeled with
QuickAIIAssay Eu-chelate protein labeling kit (BN products &
Services Oy) and Alexa Fluor 647 (AF647) Protein Labeling Kit
(Invitrogen). The labeling was performed according to the
manufacturers’ instructions. AF647 and Eu-chelate -labeled
streptavidins (AF647-SA and Eu-SA, respectively) were ordered
from Invitrogen and PerkinElmer, respectively. The unique region
of human parvovirus B19 (B19V) minor capsid protein VP1 as a
GST-fusion protein (here denoted as GST-VP1u) was expressed in
E. coli and purified for serodiagnostic use [19], and independently
labeled with Eu (using the QuickAIIAssay Eu-chelate protein
labeling kit of BN Products & Services Oy) and AF647 (using the
Protein Labeling Kit of Invitrogen), using the same protein stock,
according to the manufacturers’ instructions. GST-VP1u served as
antigen for experiments with anti-GST antibodies because its
molecular weight (53 kDa) is close to that of tetrameric SA.
Monoclonal antibody (MAb) against SA (anti-SA) (clone S3E11,
6.1 mg mL-1) was purchased from Thermo Scientific (Pierce
Protein Biology Products). Monoclonal anti-GST was from Abcam
Ltd (1 mg mL-1) and IgG-free bovine serum albumin (BSA) from
Jackson ImmunoResearch Inc. SA used for ELISA-coating was
from New England Biolabs. Human IgG fraction was purified
from human serum by High Trap protein G column (GE
Healthcare) according to the instructions. Secondary antibodies,
anti-mouse-HRP and anti-rabbit-HRP, were from Dakocytoma-
tion (P0260 and P0217, respectively). The human IgG-fraction
was purified from serum using GammaBind Plus Sepharose (GE
Healthcare) according to the manufacturers’ instructions and
under a research permit (553/E6/2001).
Enzyme-linked immunosorbent assay (ELISA)
ELISA was done as described [11] on microwell strips (96-well
format) coated overnight by 100 ml of GST-VP1u (1.5 mg mL21)
or 100 ml of SA (1.5 mg mL21) in Tris-buffered saline (TBS,
50 mM Tris-HCl, 150 mM NaCl, pH 7.4). Wells were blocked
with TBS containing 0.2% BSA (TBS-BSA). Three-fold dilution
series (from 20 nM to 0.03 nM) of the monoclonal and polyclonal
anti-GST and anti-SA antibodies were done in TBS-BSA.
TR-FRET assays
The basic protocol for all protein L TR-FRET assays was as
follows: after the reaction components were diluted in TBS-BSA,
protein L was mixed with MAb, incubated for 15 min at +37uC
and mixed with labeled SA. The final reaction volume (20 ml/well)
was pipetted onto a 384-well microplate (ProxiPlate-384 Plus F,
Black 384-shallow well Microplate from PerkinElmer). All
experiments were performed in duplicate, and the TR-FRET
values were measured with Wallac Victor2 fluorometer (PerkinEl-
mer) using the measurement and normalization protocol described
[11]. Also, protocol for the ‘‘FRET-bridge’’ assays was as
described [11].
Fab-fragment assays
Fab-fragments were generated from anti-SA MAb and purified
with a described protocol [11]. The TR-FRET signals induced by
the Fab-fragments in two-fold dilutions (200 nM to 50 nM) were
compared to those induced by intact anti-SA MAb (50 nM to
12.5 nM). Both dilution series were mixed in equal volumes with
solution containing 20 nM AF-labeled protein L and 20 nM Eu-
SA. We used 20 nM AF-labeled protein L and 20 nM Eu-SA as
control (no antibody).
Results and Discussion
Detection limits of the antibodies in ELISA
To determine whether multimericity of antigens affects the
performance of TR-FRET assays, we used GST-VP1u and SA
(tetrameric) as antigens. We first compared the detection limits of
the anti-GST and anti-SA MAbs in ELISA. The lowest
concentrations that produced a signal above background were
0.08 nM for both of the two MAbs (Fig. 1A and B, respectively).
These results imply that the sensitivities of both MAbs are roughly
equal.
Proof of principle - Binding of protein L and antigen to
the same antibody is detectable by TR-FRET
We have shown that mixtures of SA labeled separately with Eu
(donor) and AF647 (acceptor) combined with mono- or polyclonal
anti-SA readily induce TR-FRET [11]. Since TR-FRET signal is
proportional to the distance between donor and acceptor, we
explored the possibility of using a generic Fab-binding molecule
and a labeled antigen as constituents of a TR-FRET -based
homogeneous immunoassay. The experimental setup is illustrated
in Figure 2. After combining the reagents, the interacting
molecules form complexes of various types and sizes. For example,
one IgG can bind protein L without the antigen (and vice versa),
while another IgG binds both molecules. A single IgG can even
bind two antigen-protein-L pairs, one with each Fab-arm,
resulting in the formation of two FRET-pairs. To test the above
hypothesis, protein L was used as the Fab-binding moiety and SA
Homogeneous TR-FRET Antibody Assay
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and GST-VP1u as the antigens. Additionally, we wanted to know
if positioning of the labels (donor in protein L and acceptor in
antigen vs. acceptor in protein L and donor in antigen) would
affect the assay performance. We performed a set of cross-titration
experiments, in which the amount of protein L was varied
(100 nM–6.3 nM) against constant concentrations of the antibodies
and antigens (10 nM and 20 nM, respectively). The experiment was
performed in four different setups: AF-L + Eu-GST-VP1u, AF-L +
Eu-SA, Eu-L + AF-GST-VP1u and Eu-L + AF-SA. In each setup
the protein L + antigen combination was tested with a specific and a
control antibody. In the experiments with anti-SA MAb, anti-GST
MAb served as control, and vice versa. Also a buffer control was
used, which included labeled protein L and antigen, but no
antibody.
With AF-labeled protein L and Eu-labeled antigens (GST-VP1u
and SA), both of the antigens induced TR-FRET signals dose-
dependently on protein L concentration; however, the signals
induced by the Eu-GST-VP1u (Fig. 3A) were significantly higher
(.10-fold over background) than those induced by the Eu-SA
(Fig 3B) (,3-fold over background). The control antibodies (anti-
SA and anti-GST) induced background comparable to that
without antibody (Fig. 3A and 3B). Both background signals were
proportional to the AF-label concentration.
With Eu-labeled protein L in combination with AF-labeled
antigens, only AF-SA (Fig. 3C) induced an unequivocally dose-
dependent increase in signal, while AF-GST-VP1u (Fig. 3D)
induced a low TR-FRET-response. Very low background fluores-
cence, proportional to Eu concentration, was observed with the
control antibodies and in the absence of antibodies (Fig. 3C and
3D).
The above results provide a proof-of-principle for the approach
depicted in Figure 2. Furthermore, the results indicate that
increasing the concentration of protein L in the reaction mixture
in proportion to IgG produces higher TR-FRET signals, but also
increases background thus resulting in lower signal to noise (S/N)
ratios. However, even at the highest concentrations there was an
unequivocal signal-to-noise difference. Remarkably, the assay
performance was better (with both GST-VP1u and SA) when
protein L was labeled with AF (acceptor) than with Eu (donor).
Increasing the amount of acceptor-labeled molecule combined
with the time-resolved measurement does not affect the S/N ratio
to the same extent as increasing the amount of donor-labeled
molecule, which could partly explain the results. Also, changes in
the binding affinity (induced by labeling) of either protein L or the
antigens, and the degree of labeling (DOL) (number of
fluorophores, Eu or AF, per molecule) might affect the TR-FRET
signal intensities. The DOL was between 3 and 4 for all molecules
except for Eu-SA (DOL of 6-7). Since the molecules differ in their
sizes, the optimization of DOL might improve the results. Also the
positioning of the label in the molecule might affect the results by
increasing or decreasing the distance between the interacting
fluorophores. Both GST-VP1u and protein L contain .40 lysine
residues potentially reactive with the label. Unfortunately, the
labeling chemistries for Eu and SA are different, whereby the two
Figure 1. Antibody titration in ELISA. Monoclonal A) SA and B)
GST antibodies were titrated in SA- or GST coated ELISA. The error bars
represent 6 standard deviation between parallel wells.
doi:10.1371/journal.pone.0106432.g001
Figure 2. A schematic overview of the assay procedure.
doi:10.1371/journal.pone.0106432.g002
Homogeneous TR-FRET Antibody Assay
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may be incorporated in different lysine residues. This hampers
exact control over the FRET-distance between these fluorophores.
It is encouraging to see that a rather large excess (as high as
100 nM) of protein L can be used in the assay, for it to be
functional in human serodiagnostics. As the proportions of specific
IgG in acute-phase sera are typically low (,1-5%) and variable, an
excess of protein L might be required to ‘‘saturate’’ the IgG
molecules (of all specificities) in the sample.
Optimization of the protocol by cross-titration
To assess the optimal amounts of protein L and antigens relative
to antibody concentrations, we titrated the antibodies (anti-GST
and anti-SA at 50 nM–3.1 nM) against constant concentrations of
the antigens (Eu- or AF-labeled SA and GST-VP1u at 20 nM) and
protein L (Eu- or AF-labeled at 20 nM). With AF-labeled protein
L and Eu-labeled antigens both of the two antigens induced TR-
FRET signals (Fig. 4A and 4B) dose-dependently with antibody
concentrations. However, when the donor label (Eu) was in
protein L, AF-SA (Fig. 4C) induced markedly higher TR-FRET
responses than did AF-GST-VP1u (Fig. 4D), as noted above. No
TR-FRET signals were detected in the presence (or absence) of the
control antibodies in either experimental setup (AF-L and Eu-L,
Fig. 4A–D).
The signal to background ratio (18-fold) at the end point
(3.1 nM, Fig. 4A) of anti-GST antibody titration indicates that the
protein L assay could detect even lower antibody concentrations
than what was tested. Because the sensitivities with the other
antigen-antibody combinations were not as good, we decided not
to continue titration to lower antibody concentrations. The ELISA
end-point titration of anti-GST antibody showed detection
sensitivity approximately 40 times higher than with our assay
(0.08 nM vs. 3.1 nM). However, the total assay time with ELISA
(roughly 4 h) is considerably longer than that with protein L TR-
FRET assay (,30 min). The level of IgG in human serum is ,5–
15 mg/ml [20], of which antibody of a particular specificity may
comprise 0.5–2 mM, several 100-fold over the detection limit of
our assay.
To complete the cross-titration experiments, we serially diluted
protein L and antibodies together (100 nM/50 nM–6.3 nM/
3.1 nM, respectively) against constant concentrations of the
antigens (20 nM). A dose-dependent signal increase was observed
when increasing the concentrations of the antibodies and protein
L. And again, the experiments with AF-L in combination with Eu-
labeled antigens (Fig. 5A and B) gave higher TR-FRET signals
compared to Eu-labeled protein L in combination with AF-labeled
antigens (Fig. 5C and D). No TR-FRET signals were observed in
the presence or absence of control antibodies (Fig. 5A–D).
Figure 3. Eu- and AF-labeled protein L titration assays. AF-labeled protein L was titrated (100–6.3 nM) separately with A) Eu-labeled GST-VP1u
and B) Eu-labeled SA. Eu-labeled protein L was titrated (100–6.3 nM) separately with C) AF-labeled SA and D) AF-labeled GST-VP1u. The anti-GST
antibody was used as control for SA and anti-SA antibody for GST-VP1u. The third line represents a background control without antibody. The y-axis
represents response counts obtained from Victor fluorometer. The error bars represent 6 standard deviation between parallel wells.
doi:10.1371/journal.pone.0106432.g003
Homogeneous TR-FRET Antibody Assay
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Eu-labeling is more expensive and demanding than AF-labeling,
whereby it could be desirable to have the Eu-label in the protein L.
Then, the same batch of protein L could be used in combination
with different microbial antigens labeled with AF. However,
according to our cross-titration experiments with the two antigens,
SA and GST-VP1u, it seems beneficial for the assay performance
to have protein L carry the acceptor. This is mostly because
increasing the acceptor concentration in the reaction mix does not
increase the background as heavily as increasing the donor
concentration does.
Assay performance in the presence of unrelated IgG
The assay described herein relies on binding of both protein L
and antigen to a single IgG molecule. As discussed, only a fraction
of the IgG molecules in serum is specific for a given antigen while
the remaining specificities ‘‘consume’’ the protein L. We evaluated
the assay performance with regard to the presence of non-related
human IgG, by mixing anti-SA antibody with an IgG fraction of
non-immune human serum in three different ratios: 1/4 (20 nM
anti-SA, 80 nM human IgG), 1/8 (10 nM anti-SA, 70 nM human
IgG) and 1/16 (5 nM anti-SA, 75 nM human IgG). Anti-SA
antibody (at 20 nM) alone and human IgG (at 80 nM) alone
served as controls. The antigen (Eu-SA) concentration was kept
constant (10 nM), while the protein L concentration was varied
(100 nM to 200 nM). As shown in Figure 6, anti-SA antibody
mixed with non-related IgG at 1/4 ratio gave essentially the same
TR-FRET signal intensity as anti-SA antibody alone. The signals
obtained at 1/8 ratio were approximately 30% lower than those at
1/4 ratio, whereas those at 1/16 were approximately 60% lower
than those at 1/4. Altogether, the results indicate that even low
amounts of antibody (1/16 dilution, corresponding to 5 nM
specific IgG) can be detected using the new assay, using ample
amounts of AF-labeled protein L.
Protein L and antigen mixed with Fab-fragment produce
TR-FRET signal
We next determined whether TR-FRET signals induced by
labeled protein L and antigen can originate from the same Fab-
arm of the IgG molecule. To demonstrate that steric hindrance
does not prevent simultaneous binding of protein L and antigen,
we prepared anti-SA Fab-fragments by papain cleavage, and
performed titration series. The intact anti-SA MAb was used as
positive control. We compared the signals induced by Fab-
fragments to signals induced by intact antibodies. Since we have
generated Fab-fragments from an anti-SA MAb [11], we used SA
as antigen in this setup. We serially diluted the anti-SA Fab-
fragments and antibodies and mixed them separately with labeled
protein L and SA. As shown in Figure 7, the Fab fragments
produced a dose-dependent increase in TR-FRET signals,
analogously to the signals induced by the MAb. The signal
Figure 4. Antibody titration assays using AF-labeled or Eu-labeled protein L. A) Anti-GST antibody titrated against Eu-labeled GST-VP1u
and AF-labeled protein L. B) Anti-SA antibody titrated against Eu-labeled SA and AF-labeled protein L. C) Anti-SA antibody titrated against AF-labeled
SA and Eu-labeled protein L. D) Anti-GST antibody titrated against AF-labeled GST-VP1u and Eu-labeled protein L. In all setups antibody
concentrations were from 3.1 nM to 50 nM, and the antigen and protein concentration was constant (20 nM). Anti-GST antibody was used as a
control for SA assays, and anti-SA for GST assays. The third line represents a background control with no antibody. The y-axis represents response
counts obtained from Victor2 fluorometer. The error bars represent 6 standard deviation between parallel wells.
doi:10.1371/journal.pone.0106432.g004
Homogeneous TR-FRET Antibody Assay
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intensities obtained with Fab-fragments were lower than those
obtained with the intact MAb, which might be due to structural
damage due to papain. Alternatively, the divalent of nature of
intact MAb could improve signal intensities due to the diversity of
FRET-active complexes formed (see Fig. 2). Altogether, this
experiment demonstrates that protein L and antigen can form a
FRET-pair within a single Fab.
Protein L -based vs. ‘‘FRET-bridge’’ immunoassay
Finally, to compare the protein L mediated assay to the FRET-
bridge approach based on donor-labeled and acceptor-labeled
antigens [11], we compared the two at identical antibody and
antigen concentrations. Additionally, we examined the performanc-
es of both assays using mono- and tetravalent antigens (GST-VP1u
and SA, respectively). The concentrations of the corresponding
MAbs (anti-SA and anti-GST) and of the AF-labeled protein L were
Figure 5. Titration of protein L and antibodies against constant antigen concentration. A) AF-labeled protein L and anti-GST antibody
titrated against Eu-labeled GST-VP1u. B) anti-SA and AF-labeled protein L titrated against Eu-labeled SA. C) Anti-GST antibody titrated together with
Eu-labeled protein L against AF-labeled GST-VP1u. D) Anti-SA antibody titrated together with Eu-labeled protein L against AF-labeled SA. In all
experiments the antigen concentration was kept at 20 nM, and the amount of protein L was two times more than the amount of antibody. Anti-GST
antibody was used as a control for SA assays, and anti-SA for GST assays. The third line represents a background control with no antibody. The y-axis
represents response counts obtained from Victor2 fluorometer. The error bars represent 6 standard deviation between parallel wells.
doi:10.1371/journal.pone.0106432.g005
Figure 6. TR-FRET signals induced by anti-SA antibody diluted in human IgG at various concentrations. Anti-SA Antibody was diluted in
human IgG 1/4, 1/8 and 1/16, and tested with two dilutions of AF-labeled protein L: 100 nM and 200 nM, while the antigen concentration was kept
constant (10 nM). Dilutions of anti-human IgG (80 nM), anti-SA (20 nM) were used as antibody controls, and buffer with AF-L and Eu-SA at 10 nM was
used as background control. The y-axis represents response counts obtained from Victor2 fluorometer. The error bars represent 6 standard deviation
between parallel wells.
doi:10.1371/journal.pone.0106432.g006
Homogeneous TR-FRET Antibody Assay
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varied, while that of the antigens (Eu-SA and Eu-GST-VP1u) was
kept constant (10 nM). The antibody concentrations ranged from
3.1 nM to 25 nM, while the protein L concentration was always
two-fold higher than that of the antibody (6.3 nM to 50 nM). We
used AF-labeled protein L (6.3 nM to 50 nM) and 20 nM SA as
control (no antibody).
Both of the antigens, SA and GST-VP1u, induced higher TR-
FRET signals in the protein L assay (Fig. 8A and B). In fact, the
GST-VP1u antigen did not induce any signal in the FRET-bridge
assay, in line with our previous notion [11] that in the FRET-
bridge assay the multimericity of the antigen is beneficial. We have
observed that most of the TR-FRET activity in the FRET-bridge
assay is derived from large immunocomplexes consisting of more
than one IgG and two antigens [11]. We assume that the
formation of these highly TR-FRET-active immunocomplexes is,
to some extent, hindered by monomeric antigens. In theory, a
tetrameric antigen should bind more antibodies than a monomeric
antigen, at least in case of MAb. In the protein L assay, SA
induced twice higher TR-FRET signals compared to GST-VP1u.
Hence, it seems that also in the protein L approach, multimericity
of the antigen is beneficial, although the higher DOL of Eu-SA
might also explain the observed difference in performance of the
two antigens. One reason for the induction of higher TR-FRET
responses in the protein L assay could be that the recombinant
protein L contains four k light chain-binding domains. However, it
is possible that binding of several Igs by a single protein L molecule
would be sterically hindered.
Conclusions
Herein we describe a novel TR-FRET -based immunoassay
that relies on simultaneous binding of fluorophore-labeled protein
L and fluorophore-labeled antigen to an IgG molecule. We show
that the assay principle is functional, and that the FRET signal can
be generated by binding of the protein L and antigen to the same
Fab arm of IgG. We also demonstrate that the labeled protein L in
excess can be used to ‘‘saturate’’ a mixture of IgG molecules,
enabling the use of this approach in serodiagnostics. Comparison
of the new assay to the previously reported FRET-bridge assay
showed the former to be more sensitive and less dependent on
antigen multimericity. The main advantages of protein L assay as
compared to commonly utilized immunological assays such as
ELISA, are the assay time (Protein L assay ,30 minutes vs.
ELISA ,4 h), the wash-free format, and the ease of performance.
After providing this proof-of-concept for the test system using
readily accessible materials we will adapt the approach for
serodiagnostics of infectious diseases.
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Figure 7. The performance of Fab-fragments generated from
anti-SA MAb in the protein L assay. Fab-fragments were diluted
from 200 nM to 50 nM, and a dilution series (50 nM to 12.5 nM) of anti-
SA MAb acting as control was tested in parallel. The third line
represents a control for fluorescence background induced by AF-
labeled protein L and Eu-SA. The y-axis represents response counts
obtained from Victor2 fluorometer. The error bars represent 6 standard
deviation between parallel wells.
doi:10.1371/journal.pone.0106432.g007
Figure 8. Protein L vs. FRET-bridge assay. Dilutions series (25–
3.1 nM) of the antibodies, A) anti-SA antibody and B) anti-GST, were
tested in parallel with both of the assay approaches. Protein L was
titrated along with the antibody concentration, representing concen-
trations from 50 to 6.3 nM. Concentrations of GST-VP1u and SA were
constant at 10 nM. The third line in both figures represents a control for
fluorescence background induced by AF-labeled protein L and the
antigen. The y-axis represents response counts obtained from Victor2
fluorometer. The error bars represent 6 standard deviation between
parallel wells.
doi:10.1371/journal.pone.0106432.g008
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